ISID organised a webinar on “State of Vaccine Manufacturing in India: Structure and Competitiveness” on June 23, 2023. Dr Shailendra Hooda, Associate Professor, ISID, made the presentation. The presentation was discussed by distinguished panellists, comprising Prof Sudip Chaudhuri, Visiting Faculty, Centre for Development Studies, Thiruvananthapuram; Dr Y Madhavi, Chief Scientist and Professor, Academy of Scientific and Innovative Research, Council of Scientific and Industrial Research-National Institute of Science Communication and Policy Research; and Mr K M Gopakumar, Legal Advisor, Third World Network. Dr Anjali Tandon, Associate Professor, ISID, moderated the webinar.
Click here to REGISTER | INVITE
Meeting ID: 894 5352 0899
Passcode: 20230623
Abstract: Vaccine manufacturing in India has historically been centered around producing a wide-variety of conventional vaccines that made the country self-sufficient as well as a net exporter of basic vaccines. However, overtime, other safe and efficacious vaccines that follow technologically more advanced manufacturing processes became available in the market against some high burdened diseases, their increased uptake made the country import dependent. In the second half of 2000s when manufacturing capacity of public sector was being dismantled, India became a big market for imported vaccines (e.g., import penetration rate increased from 10.6% to 62.5% between 2007-08 to 2013-14) since then and export got affected adversely. Despite such repercussions, India continued to enjoy comparative advantage (RCA>1) and trade surplus due to high acceptability of Indian vaccines in developing countries market. High R&D intensity and active State support are critical for making the country self-reliant and self-sufficient in vaccine development and manufacturing, and addressing future health challenges like the Coronavirus.